Floatz logo

Hyoscine

Sialorrhea

Mersey Care NHS TrustSmall moleculePhase 1/2Dormant
CCC
52/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
37/ 100
Competitive Position
95/ 100

Competitive context

0 Active assets in the Sialorrhea cohort.

Asset / SponsorPhaseRating
Botulinum Toxin Type B
Solstice Neurosciences, LLC, a subsidiary of US WorldMeds, LLC
Phase 3BB
Glycopyrrolate
Ottawa Hospital Research Institute
Phase 2BB
INCOBOTULINUMTOXINA
Beth Israel Deaconess Medical Center
Phase 2B
Clozapine
D

Same molecule, other indications

Hyoscine is also rated in:

Bariatric Surgery CandidateDormant
BB
Indicative ·
64 / 100
View asset →
Systemic Inflammatory Response SyndromeDormant
BB
Indicative ·
64 / 100
View asset →
Postoperative Pain, AcuteDormant
BB
Indicative ·
64 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →